113 related articles for article (PubMed ID: 36315382)
21. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
22. Dosimetry assessment of theranostic Auger-emitting radionuclides in a micron-sized multicellular cluster model: A Monte Carlo study using Geant4-DNA simulations.
Salim R; Taherparvar P
Appl Radiat Isot; 2022 Oct; 188():110380. PubMed ID: 35868198
[TBL] [Abstract][Full Text] [Related]
23. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
Elgqvist J; Timmermand OV; Larsson E; Strand SE
Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
[TBL] [Abstract][Full Text] [Related]
24. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position.
Marnouche EA; Hadadi K; Abdelhak M; Benlemlih M; Hommadi M; Zaghba N; Andaloussi Saghir K; Elmarjany M; Sifat H; Mansouri H
Cancer Radiother; 2021 Apr; 25(2):161-168. PubMed ID: 33454191
[TBL] [Abstract][Full Text] [Related]
26. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
27. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
[TBL] [Abstract][Full Text] [Related]
28. Assessment of S values in stylized and voxel-based rat models for positron-emitting radionuclides.
Xie T; Zaidi H
Mol Imaging Biol; 2013 Oct; 15(5):542-51. PubMed ID: 23558509
[TBL] [Abstract][Full Text] [Related]
29. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
30. A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom.
Kostou T; Papadimitroulas P; Loudos G; Kagadis GC
Phys Med Biol; 2016 Mar; 61(6):2333-55. PubMed ID: 26930000
[TBL] [Abstract][Full Text] [Related]
31. Testicular doses in image-guided radiotherapy of prostate cancer.
Deng J; Chen Z; Yu JB; Roberts KB; Peschel RE; Nath R
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e39-47. PubMed ID: 21489702
[TBL] [Abstract][Full Text] [Related]
32. Effect of respiratory motion on internal radiation dosimetry.
Xie T; Zaidi H
Med Phys; 2014 Nov; 41(11):112506. PubMed ID: 25370665
[TBL] [Abstract][Full Text] [Related]
33. Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties.
Ree SM; Greenwood H; Young JD; Roberts R; Livens FR; Heath SL; Sosabowski JK
Nucl Med Commun; 2024 Jun; 45(6):465-473. PubMed ID: 38465420
[TBL] [Abstract][Full Text] [Related]
34. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
35. Computational modeling of radiobiological effects in bone metastases for different radionuclides.
Liberal FDCG; Tavares AAS; Tavares JMRS
Int J Radiat Biol; 2017 Jun; 93(6):627-636. PubMed ID: 28276897
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: Influence of radionuclide choice.
Tamborino G; Nonnekens J; Struelens L; De Saint-Hubert M; Verburg FA; Konijnenberg MW
Phys Med; 2022 Apr; 96():90-100. PubMed ID: 35245708
[TBL] [Abstract][Full Text] [Related]
37. Role of lipid-soluble complexes in targeted tumor therapy.
Thakur ML; Coss R; Howell R; Vassileva-Belnikolovska D; Liu J; Rao SP; Spana G; Wachsberger P; Leeper DL
J Nucl Med; 2003 Aug; 44(8):1293-300. PubMed ID: 12902421
[TBL] [Abstract][Full Text] [Related]
38. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
39. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
40. 119Sb--a potent Auger emitter for targeted radionuclide therapy.
Thisgaard H; Jensen M
Med Phys; 2008 Sep; 35(9):3839-46. PubMed ID: 18841834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
